TECPR2 Foundation, Forge Biologics Partner on AAV Gene Therapy
The TECPR2 Research Foundation and Forge Biologics partners to advance development and manufacturing of an investigational AAV gene therapy for TECPR2-related disorder.
TECPR2-related Disorder | 30/09/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy